Sanofi (NASDAQ:SNY) Hits New 1-Year Low – Should You Sell?

Sanofi (NASDAQ:SNY) shares reached a new 52-week low on Friday. The company traded as low as $40.68 and last traded at $40.7150, with a volume of 210330 shares. The stock had previously closed at $40.94.

Wall Street Analyst Weigh In

SNY has been the subject of a number of research reports. Weiss Ratings lowered Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, August 3rd. Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 29th. HSBC restated a “buy” rating on shares of Sanofi in a report on Thursday, September 10th. Royal Bank Of Canada assumed coverage on Sanofi in a report on Tuesday, September 8th. They set a “sector perform” rating on the stock. Finally, Morgan Stanley set a $49.00 price target on shares of Sanofi in a research report on Wednesday, July 8th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $49.50.

Sanofi Trading Down 0.3%

The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.64 and a current ratio of 0.99. The firm has a market capitalization of $98.99 billion, a P/E ratio of 21.37, a price-to-earnings-growth ratio of 1.28 and a beta of 0.35. The firm has a 50 day moving average price of $43.77 and a two-hundred day moving average price of $44.28.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, July 30th. The company reported $2.41 earnings per share (EPS) for the quarter. Sanofi had a return on equity of 14.19% and a net margin of 8.66%.The company had revenue of $13.36 billion for the quarter. During the same period last year, the firm earned $3.24 earnings per share. The firm’s revenue for the quarter was up 16.0% on a year-over-year basis. On average, equities research analysts expect that Sanofi will post 5.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Tidal Investments LLC boosted its position in Sanofi by 21.5% during the 2nd quarter. Tidal Investments LLC now owns 165,289 shares of the company’s stock worth $7,051,000 after acquiring an additional 29,283 shares during the period. Assetmark Inc. grew its stake in Sanofi by 14.8% during the 1st quarter. Assetmark Inc. now owns 509,464 shares of the company’s stock valued at $24,546,000 after acquiring an additional 65,796 shares in the last quarter. AMG National Trust Bank acquired a new position in shares of Sanofi in the 1st quarter valued at about $2,719,000. Manning & Napier Advisors LLC lifted its position in shares of Sanofi by 728,134.8% in the first quarter. Manning & Napier Advisors LLC now owns 1,194,305 shares of the company’s stock worth $57,542,000 after purchasing an additional 1,194,141 shares in the last quarter. Finally, Goodman Financial Corp purchased a new stake in shares of Sanofi in the first quarter worth approximately $9,833,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

About Sanofi

Sanofi is a global healthcare company headquartered in France that develops, manufactures and markets prescription medicines and vaccines. Its portfolio serves patients across areas including immunology, rare diseases, rare blood disorders, neurology, oncology and inflammatory conditions, as well as other specialty-care and general-medicine categories.

The company is also a major vaccine producer through its vaccines business, which supplies products for diseases such as influenza, polio, pertussis, meningitis and dengue.